Angewandte Chemie (International ed. in English) · 2025
Sonoelectric Nanonet-Activated Extracellular Electron Transfer for Wireless Non-Genetic Stimulation of Pancreatic β Cells.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
You Yanling, Jiang Junjie, Chen Zhixin, Zhu Ya-Xuan, Chen Yihan, Lin Han, Shi Jianlin
Аннотация
Engineered cell-based therapy is an emerging approach for treating intractable diseases, in which the remote control of cellular behavior necessitates robust physical input-sensing-response systems. Nanomaterials represent promising tools to enable wireless remote control of cells. To achieve this, the precise anchoring of nanomaterials to target cells is crucial for nanomaterial-engineered cells to prevent undesired effects such as endocytosis and diffusion. Herein, we describe a general cell engineering strategy using nanomaterials to achieve remote-controlled and sustained insulin release from the engineered pancreatic β cells. The prepared nanocomposite, termed TCN, is composed of defect-rich titanium oxide quantum dots with ultrasound-electric conversion effect and fibrous carbon substrate. In vitro experiments demonstrate that the TCN enables cell surface engineering through carbon substrate adsorption onto pancreatic β cells without chemical modification, while the TiOx quantum dots of TCN enable effective ultrasound-responsive electrical stimulation to activate insulin release from β cells. Furthermore, we demonstrate that the subcutaneous implantation of TCN-engineered β cell complexes in type 1 and type 2 diabetic mice enables the restoration of normoglycemia by ultrasound stimulation, establishing a nanomaterials-enabled controlled cell therapy paradigm for diabetes.